Skip Nav Destination
Issues
1 May 2017
-
Cover Image
Cover Image
Epidemiologically, an inverse correlation has been reported between the intake of soy foods and esophageal cancer, which is the 8th most common cancer worldwide and the 6th most common cause of cancer death with an estimated 400,000 deaths or 4.9% of total cancer deaths. Pin1 is a critical therapeutic and preventive target in esophageal cancer because of its positive regulation of β-catenin and cyclin D1. Indeed, up-regulation of Pin1 levels has been observed clinically and is closely correlated with poor survival of esophageal cancer patients. The cover image reveals the direct binding of 6,7,4′-trihydroxyisoflavone, a major metabolite of daidzein, at both the WW and PPIase domains of Pin1. See article by Lim et al. (beginning on page 308) for more information about this natural inhibitor of the Pin1 protein for suppressing esophageal cancer development. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Editorial
Review
Research Articles
No Decreased Risk of Gastrointestinal Cancers in Users of Metformin in The Netherlands; A Time-Varying Analysis of Metformin Exposure
Roy G. de Jong; Andrea M. Burden; Sander de Kort; Myrthe P. van Herk-Sukel; Pauline A. Vissers; Paddy K. Janssen; Harm R. Haak; Ad A. Masclee; Frank de Vries; Maryska L. Janssen-Heijnen
A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers
Jason R. Gee; Daniel R. Saltzstein; KyungMann Kim; Jill Kolesar; Wei Huang; Thomas C. Havighurst; Barbara W. Wollmer; Jeanne Stublaski; Tracy Downs; Hasan Mukhtar; Margaret G. House; Howard L. Parnes; Howard H. Bailey
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.